SLC31A1 and central nervous system cancer: We ranked the TCGA glioma patient samples by the expression level of SLC31A1, and the glioma cohort was classified into low- and high-expression groups according to the expression levels of SLC31A1. Then, we compared the prognosis difference between the two groups.